2021 / 03

Next Paper
DOI: 10.47183/mes.2021.021

CLINICAL CASE

Central vein sign for differential diagnosis of demyelinating diseases of CNS

Belov SE1,2, Gubsky IL2, Lelyuk VG2, Boyko AN1,2
About authors

1 Pirogov Russian National Research Medical University, Moscow, Russia

2 Federal Center for Brain Research and Neurotechnologies of FMBA, Moscow, Russia

Correspondence should be addressed: Alexey N. Boyko
Ostrovityanova, 1, 117437, Москва; moc.liamg@31naokyob

About paper

Author contribution: Belov SE — literature analysis, study design, recruitment of patients, clinical analysis, manuscript preparation; Gubsky IL — study design, MRI examinations, MRI data analysis, manuscript preparation; Lelyuk VG — study design, MRI data analysis, manuscript preparation; Boyko AN — study design, recruitment of patients, clinical analysis, manuscript preparation.

Compliance with ethical standards: informed consent was obtained from both patients.

Received: 2021-07-15 Accepted: 2021-08-04 Published online: 2021-08-18
|
  1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17 (2): 162–73. DOI: 10.1016/S1474-4422(17)30470-2.
  2. Solomon AJ. Diagnosis, Differential Diagnosis, and Misdiagnosis of Multiple Sclerosis. Continuum (Minneap Minn). 2019; 25 (3): 611–35. DOI: 10.1212/CON.0000000000000728.
  3. Solomon AJ, Klein EP, Bourdette D. "Undiagnosing" multiple sclerosis: the challenge of misdiagnosis in MS. Neurology. 2012; 78 (24): 1986–91. DOI: 10.1212/WNL.0b013e318259e1b2.
  4. Clarke MA, Pareto D, Pessini-Ferreira L, et al. Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. Am J Neuroradiol. 2020; 41 (6): 1001–8 DOI: 10.3174/ ajnr.A6547.
  5. Oh J, Sicotte NL. New imaging approaches for precision diagnosis and disease staging of MS? Mult Scler. 2020; 26 (5): 568–75. DOI: 10.1177/1352458519871817.
  6. Tallantyre EC, Brookes MJ, Dixon JE, Morgan PS, Evangelou N, Morris PG. Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI. Neurology. 2008; 70: 2076–8. DOI: 10.1212/01.wnl.0000313377.49555.2e.
  7. Tallantyre EC, Dixon JE, Donaldson I, Owens T, Morgan P S, Morris PG, Evangelou N. Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions. Neurology. 2011; 76: 534–9 DOI: 10.1212/WNL.0b013e31820b7630.
  8. Mistry N, Dixon J, Tallantyre E, Tench C, Abdel-Fahim R, Jaspan T, Morgan PS, Morris P, Evangelou N. Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain. JAMA Neurol. 2013; 70 (5): 623–8 DOI: 10.1001/jamaneurol.2013.1405.
  9. Maggi P, Absinta M, Grammatico M, et al. Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol. 2018; 83 (2): 283–94 DOI: 10.1002/ana.25146.
  10. Maggi P, Absinta M, Sati P, et al. The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study. Mult Scler. 2020; 26 (4): 421–32 DOI: 10.1177/1352458519876031.
  11. Campion T, Smith RJP, Altmann DR, et al. FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis? Eur Radiol. 2017; 27 (10): 4257–63. DOI: 10.1007/s00330-017-4822-z.
  12. Clarke MA, Samaraweera AP, Falah Y, et al. Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty. Mult Scler. 2020; 26 (4): 433–41. DOI: 10.1177/1352458519882282.
  13. Cortese R, Magnollay L, Tur C, et al. Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. Neurology. 2018; 90 (14): e1183-e1190. DOI: 10.1212/WNL.0000000000005256.
  14. Sparacia G, Agnello F, Gambino A, Sciortino M, Midiri M. Multiple sclerosis: High prevalence of the 'central vein' sign in white matter lesions on susceptibility-weighted images. Neuroradiol J. 2018; 31 (4): 356–61. DOI: 10.1177/1971400918763577.
  15. Suh CH, Kim SJ, Jung SC, Choi CG, Kim HS. The "Central Vein Sign" on T2*-weighted Images as a Diagnostic Tool in Multiple Sclerosis: A Systematic Review and Meta-analysis using Individual Patient Data. Sci Rep. 2019; 9 (1): 18188. DOI: 10.1038/s41598019-54583-3.
  16. Sinnecker T, Clarke MA, Meier D, et al. Evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis. JAMA Neurol. 2019; 76 (12): 1446–56. DOI: 10.1001/ jamaneurol.2019.2478.
  17. Bhandari A, Xiang H, Lechner-Scott J, Agzarian M. Central vein sign for multiple sclerosis: A systematic review and meta-analysis. Clin Radiol. 2020; 75 (6): 479.e9–479.e15. DOI: 10.1016/j. crad.2020.01.011.
  18. Gaitán MI, Yañez P, Paday Formenti ME, Calandri I, Figueiredo E, Sati P, et al. SWAN-Venule: An Optimized MRI Technique to Detect the Central Vein Sign in MS Plaques. Am J Neuroradiol. 2020; 41 (3): 456–60. DOI: 10.3174/ajnr.A6437.
  19. Sati P, Oh J, Constable RT, Evangelou N, Guttmann CR, Henry RG, et al. NAIMS Cooperative. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol. 2016; 12 (12): 714–22. DOI: 10.1038/nrneurol.2016.166.
  20. Belov SE, Boyko AN. The symptom of the central vein in the differential diagnosis of multiple sclerosis. Neurology, Neuropsychiatry, Psychosomatics, 2020, 12 (Suppl. 1): 29–32. Russian.